Research Registry FAQs
The Registry is required to conceal a member's identity and personal information from researchers and organizations unless consent is granted by the Registry member. The database is kept under tight security at all times. This means that it is password protected and inaccessible from the Internet. Also, all hard copies of personal information are kept under lock and key. Only the Registry Director and Coordinators have access to a member's personal information.
Once you have given your consent to participate in a study, you are considered enrolled and you may proceed with the outlined study activities. Some of these activities may be interviews, surveys, medical tests, educational sessions, or the administration of certain treatments.
The list of research sponsors is very large and includes both public and private sources. Every study should state the funding source. Some small studies may be unfunded. Some of the common sponsors include:
- The U.S. Department of Health and Human Services, including the National Institutes of Health.
- Pharmaceutical Manufacturers
- Biotechnology Companies
- Not-for-profit organizations, such as the Alpha-1 Foundation
Didn't find what you were looking for? Submit your question below.
Submit your question
ACT Study FAQs
For example, if your results return showing an MZ genotype, you are a carrier because you inherited one normal copy (M) and one abnormal copy (Z). You do not have Alpha-1; you are a carrier. Your MZ genotype will produce reduced amounts of AAT but should provide enough to protect you from symptoms, unless you smoke. As a carrier of Alpha-1, you will pass either the M or the Z to your children. The only way to find out which gene they received from you is to test them.
If you are diagnosed as deficient for Alpha-1 or a carrier, you can contact the resources listed in the brochures which are provided with your result letter.
You should avoid risk factors such as smoking, secondhand smoke, dust, harmful fumes and excessive alcohol use.
You should get regular vaccinations to protect against bacteria infections from pneumococcal pneumonia and Haemophilus influenza. An annual influenza vaccine is highly recommended.
You can also inform your family members and urge them to test for Alpha-1.
Genetic Counseling FAQs
Alpha-1 antitrypsin deficiency (Alpha-1, AATD) is an
inherited condition that raises the risk for lung disease. Risk for liver
disease is also increased in many people with Alpha-1. Lung disease typically
occurs in adulthood, while liver disease can occur in children or adults.
People with Alpha-1 do not produce a protein called alpha-1 antitrypsin
Alpha-1 antitrypsin is a protein that is made in the liver. It is then secreted into the blood. Alpha-1 antitrypsin is needed in circulation to protect the lungs. Without enough of it, the lungs are at risk to develop chronic obstructive pulmonary disease (COPD).
The way each person's body makes Alpha-1 antitrypsin is
determined by genes. Everyone has two copies of the alpha-1 gene, one inherited
from each parent. Abnormal Alpha-1 genes result in Alpha-1 deficiency. The “Z”
mutation produces abnormal alpha-1 antitrypsin that builds up in the liver,
rather than passing into circulation. People with two Z genes (ZZ) have high
lifetime risks for lung and liver disease. There are other mutations that can
cause Alpha-1, too. For example, the S, F, and I mutations are different
abnormal versions of the gene. The normal gene for Alpha-1 is called “M”.
MM is the normal gene combination.
Alpha-1 is an inherited risk. Not everyone with Alpha-1 will develop symptoms, or the same symptoms. It is important to know about Alpha-1 because there are ways to reduce risks (such as avoiding smoking), and medical care to detect and treat symptoms for better outcomes. For people with Alpha-1 COPD, a specific therapy, called augmentation therapy, may be recommended. Because Alpha-1 genes run in families, knowing about Alpha-1 can be important for relatives and family planning.
Genes are the genetic “blueprint” for how our bodies
develop and function. Genes are units of DNA. People have about 25,000 genes. They
are found inside the nucleus of our cells. Genes are passed from parent to
child. People get one copy of each gene from their mother and one from their
father (sex chromosome genes excluded).
Everyone has changes in their genes that make them unique. Changes in genes can be neutral variants or cause problems. Changes that cause disease or raise risks are called mutations. Mutations in one specific gene cause Alpha-1 deficiency. The gene for Alpha-1 is called SERPINA1.
Alleles are different versions of the same gene. The normal Alpha-1 allele is called "M." Abnormal allelles, also called mutations, occur due to changes in the DNA of the Alpha-1 gene that affect how Alpha-1 is made. Mutations result in an abnormal quantity and/or abnormal function of alpha-1 antitrypsin.
The most common deficiency alleles are "S" and "Z." There are also more than 100 other rarer deficiency alleles (such as F and I and null alleles). The M allele (M1, M2, M3) produces normal Alpha-1 protein (normal quantity and normal function). Different deficiency alleles have different effects on Alpha-1 level and function, thus different allele combinations (genotypes) lead to different disease risks.
M - The M allele is normal (normal alpha-1 antitrypsin quantity and function).
F – The F mutation produces a dysfunctional alpha-1 protein product.
Z - The Z mutation produces an abnormal protein product that gets trapped in the liver and reduces the quantity of alpha-1 antitrypsin (AAT) in the blood.
S - The S mutation causes a moderate reduction in the quantity of alpha-1 antitrypsin (AAT) in the blood.
I - The I mutation results in a reduced quantity of Alpha-1 protein in the blood.
Null - Null mutations make no alpha-1 antitrypsin (AAT); no AAT is produced in the liver or found in the blood as a result of null mutations. There are many different null mutations.
Rare - Rare mutations may make altered forms of alpha-1 antitrypsin (AAT). There are many different rare mutations. Most rare mutations reduce the quantity of alpha-1 antitrypsin (AAT) in the blood. A few rare mutations cause alpha-1 trapping in the liver or altered alpha-1 function. Contact the genetic counselor for information about any specific rare mutation.
A genotype is the combination of Alpha-1 alleles you have. The normal genotype is MM (two copies of the normal M allele). Carrier genotypes include MS, MZ, MF, MI, Mnull and other genotypes where one allele is a normal M and the other is abnormal.
Deficiency genotypes include ZZ, SZ, FZ, IZ, Znull and some others where a person has two abnormal genes.
There are many more rare Alpha-1 genotypes. Contact the genetic counselor if you have questions about finding out your genotype or what your genotype means.
Everyone has two copies of the Alpha-1 gene. Severe deficiency (low levels) of alpha-1 antitrypsin occurs when both copies have a mutation. A mild deficiency, or intermediate alpha-1 antitrypsin level, may occur in carriers with one abnormal gene.
Genes are inherited. We get one copy of the Alpha-1 gene from our mother and the other from our father. If you have children, you pass on one of your two Alpha-1 genes, and the child gets their second Alpha-1 gene from the other parent. When both parents have one or more abnormal Alpha-1 genes there is a risk to have a child with severe deficiency.
Alpha-1 carriers are people who have one normal Alpha-1 gene (called M) and one abnormal Alpha-1 gene (S, Z, F, I, other). Carrier genotypes include MS, MZ, MF, MI, M-Other.
Carriers may be termed “mildly deficient” because this combination of genes leads to a lower Alpha-1 level than expected for most people with two normal genes (MM) but higher than that of someone with severe deficiency caused by two abnormal genes (ZZ, SZ).
Most carriers do not develop Alpha-1 related symptoms; however, recent research has shown that MZ carriers who smoke are at high risk for COPD. MZ carriers also have a small increased risk for liver disease. Carriers should avoid smoking and live a healthy lifestyle.
There are over 20 million Alpha-1 carriers in the US. Being an Alpha-1 carrier is more common than many people know. About 2-3% of North Americans are carriers of the Z mutation (MZ) and about 5% carry the S (MS). Carriers of other mutations such as the F, I, and rare/null mutations are less common and exact rates are not known. A person's individual chance to be a carrier depends on their ethnic background and family history.
The good news is that most carriers never have health problems due to
their Alpha-1 mutation. However, research continues to better define select
groups of people with higher risk for COPD. It is possible that certain carrier
sub-groups with higher risk will be defined in the future. Any person
experiencing symptoms or a change in their health should see a healthcare provider for personal evaluation.
Carriers have a 50% chance of passing on their abnormal Alpha-1 gene to each child, so, any child of a carrier has a 50% chance to be a carrier, too. If two carriers have children together, there is a risk to have a child with severe Alpha-1 antitrypsin deficiency. This happens when the child inherits an abnormal gene from both the mother and the father.
Pi stands for Protease Inhibitor. Alpha-1 antitrypsin is a type of protein called a protease inhibitor, so Pi type is the type(s) of Alpha-1 protein produced by your body (in your liver).
The normal Pi type is M. Normal M variants include M1, M2 and M3. Abnormal Pi types included Z, S, F, I and others.
In most cases your Pi type and your genotype are the same since the genes instruct the alpha-1 antitrypsin your body makes (e.g. genotype MZ will have Pi MZ). Exceptions include people on augmentation therapy and who have had a liver transplant. In these cases a normal Pi M is detected due to the treatment and may not correlate with the person’s genes.
Contact the genetic counselor if you have questions about your Pi type.
According to the 2016 Guidelines for The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult:
- All individuals with COPD regardless of age or ethnicity should be tested for AATD.
- All individuals with unexplained chronic liver disease should be tested for AATD.
- All individuals with necrotizing panniculitis, granulomatosis with polyangiitis, or unexplained bronchiectasis should be tested for AATD.
- Parents, siblings, and children, as well as extended family of individuals identified with an abnormal gene for AAT, should be provided genetic counseling and offered testing for AATD (see guideline document for special considerations about testing minors).
There are several options for getting tested.
1. The Alpha-1 Coded Testing (ACT) Study is a free and confidential testing program supported by the Alpha-1 Foundation. Testing through this program is voluntary and nobody gets your results except you. You will receive your results in the mail. The genetic counselor is available to help you understand your results.
To receive an ACT kit, complete the informed consent and research questionnaire at www.alphaoneregistry.org. Adults (18 and over) are required to complete their own forms. Parents and legal guardians may complete the forms for their minor children and those in legal guardianship.
2. You may ask your healthcare provider to order testing for Alpha-1. Many labs offer Alpha-1 testing. Several Alpha-1 specialty labs (GeneAidyx, Biocerna LLC and AlphaCenter) provide free testing. Ask your healthcare provider if you have questions about which test is being ordered and details of the test. If your healthcare provider orders your test, the results will go to that healthcare provider to be shared with you.
3. 23andMe received FDA approval to report Alpha-1 results for the S and Z mutations beginning in April, 2017. Many other genetic results are available to consumers in addition to Alpha-1 results through 23andMe.4. Some expanded genetic carrier screens (that people may have as part of fertility or prenatal care) include Alpha-1, among other conditions.
You can call the Alpha-1 genetic counselor to discuss your results no matter how you are tested.
Alpha-1 testing requires a blood sample. This may be dried blood spots which are obtained by a finger stick or a blood draw.
Only a blood test can diagnose or rule out Alpha-1.
It depends on the lab. There are several ways to test for Alpha-1. Some labs use more than one to ensure accuracy.
An immunoassay, also called a ‘level’, measures the quantity of Alpha-1 in your blood. This is done on one of two scales, either uM or mg/dL, and is reported as a number. This is helpful to see if you have a low level that indicates deficiency.
Phenotyping looks at the Alpha-1 protein(s) in your blood using a technique called isoelectric focusing. The results are two letters called a Pi type, which includes one or two letters (e.g. Pi M, Pi Z, Pi MZ).*
Genotyping spot checks the Alpha-1 gene for specific mutations. The results are two letters called a genotype* or describe whether 0, 1 or 2 mutations were found.
- Genotyping and phenotyping give you the same result in most cases.
Gene sequencing spells out the DNA sequence of the Alpha-1 gene. This is useful for clarification of less common Alpha-1 gene mutations.
You should contact the lab that performs testing for your office to obtain results or testing supplies. The Alpha-1 genetic counselor is not able to obtain clinical test results or provide supplies for any medical office. The Alpha-1 genetic counselor is available to interpret and discuss any Alpha-1 results after you have them.
You should always discuss your personal medical recommendations with a personal healthcare provider.
You should always discuss your personal medical recommendations with a personal healthcare provider.